1 |
Hajian M, Erfani-moghadam V, Arabi MS, Soltani A, Shahbazi M. A comparison between optimized PLGA and CS-Alg-PLGA microspheres for long-lasting release of glatiramer acetate. Journal of Drug Delivery Science and Technology 2023. [DOI: 10.1016/j.jddst.2023.104355] [Reference Citation Analysis]
|
2 |
Plohl O, Fric K, Filipić A, Kogovšek P, Tušek Žnidarič M, Zemljič LF. First Insights into the Antiviral Activity of Chitosan-Based Bioactive Polymers towards the Bacteriophage Phi6: Physicochemical Characterization, Inactivation Potential, and Inhibitory Mechanisms. Polymers (Basel) 2022;14. [PMID: 36015613 DOI: 10.3390/polym14163357] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
3 |
Petrov AM, Votintseva MV, Stolyarov ID. Safety of pathogenetic therapy for multiple sclerosis during the COVID-19 pandemic. Annals of Clinical and Experimental Neurology 2022;16:70-77. [DOI: 10.54101/acen.2022.2.8] [Reference Citation Analysis]
|
4 |
Ortenberg EA, Suplotova LA. Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review). Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-10-40-45] [Reference Citation Analysis]
|
5 |
Gao K, Wang R, Chen J, Tepe JJ, Huang F, Wei GW. Perspectives on SARS-CoV-2 Main Protease Inhibitors. J Med Chem 2021;64:16922-55. [PMID: 34798775 DOI: 10.1021/acs.jmedchem.1c00409] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
|
6 |
Kamat S, Kumari M, Jayabaskaran C. Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2. J Control Release 2021;338:813-36. [PMID: 34478750 DOI: 10.1016/j.jconrel.2021.08.046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
|